ESMO Asia 2022 | Unmet needs in chemoradiotherapy for esophageal cancer

Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses the unmet needs in chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Dr Kato discusses the combination of chemoradiotherapy and immune checkpoint inhibitors in trials such as KEYNOTE-975 (NCT04210115) and RATIONALE-311 (NCT03957590), as well as advances in the area of perioperative chemoimmunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.